The study focuses on patients who have undergone surgery to replace their aortic valve with a bioprosthetic valve due to valvular heart disease. The purpose of the study is to compare two treatments to see which is more effective in preventing complications. The treatments being compared are apixaban, a medication that helps prevent blood clots, and aspirin, which is commonly used to reduce the risk of heart attacks and strokes.
Participants in the study will be randomly assigned to receive either apixaban or aspirin. The study will last for about 120 days, during which time the health of the participants will be closely monitored. The main goal is to see if apixaban is better than aspirin at preventing serious health problems such as death, heart attacks, strokes, blood clots in the lungs or veins, and issues with the new heart valve.
Throughout the study, the safety of the participants will be a priority, and any side effects, especially bleeding, will be carefully tracked. The study aims to provide valuable information that could improve the care of patients with bioprosthetic aortic valves in the future.



France